Advertisement
U.S. markets closed
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • Dow 30

    39,807.37
    +47.29 (+0.12%)
     
  • Nasdaq

    16,379.46
    -20.06 (-0.12%)
     
  • Russell 2000

    2,124.55
    +10.20 (+0.48%)
     
  • Crude Oil

    83.11
    -0.06 (-0.07%)
     
  • Gold

    2,254.80
    +16.40 (+0.73%)
     
  • Silver

    25.10
    +0.18 (+0.74%)
     
  • EUR/USD

    1.0774
    -0.0020 (-0.18%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2623
    +0.0000 (+0.00%)
     
  • USD/JPY

    151.3290
    -0.0430 (-0.03%)
     
  • Bitcoin USD

    69,942.68
    -446.01 (-0.63%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,369.44
    +201.37 (+0.50%)
     

Today’s Research Reports on Trending Tickers: Gilead Sciences and Abbott Laboratories

NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 percent to close at 24,893.49, for its fourth consecutive daily gain, while the S&P 500 Index spiked 1.34 percent to close at 2,698.63. The Nasdaq Composite Index surged 1.86 percent to close at 7,143.62.

"Anything with inflation seems like a hot button nowadays, but it is a bit of a red herring here: higher inflation and higher rates are symptoms of economic health. And while inflation is rising it's still below trend," said Karyn Cavanaugh, senior market strategist at Voya Financial, according to MarketWatch.

"At this point it's not inflation but reflation and the Fed will not pull the trigger that fast," said Cavanaugh.

RDI Initiates Coverage on:

Gilead Sciences, Inc.
https://rdinvesting.com/news/?ticker=GILD

Abbott Laboratories
https://rdinvesting.com/news/?ticker=ABT

Gilead Sciences' stock moved 1.27% higher Wednesday, to close the day at $81.82. The stock recorded a trading volume of 7,063,271 shares, which was below its three months average volume of 8,767,400 shares. In the last year, Gilead Sciences' shares have traded in a range of 70.05 - 89.54. The share price has gained 16.80% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $79.29 is greater than its 200-day moving average of $77.68. Shares of the company are trading at a Price to Earnings ratio of 23.31. Shares of Gilead Sciences have gained roughly 3.54 percent in the past month and are up 14.21 percent year-to-date.

Access RDI's Gilead Sciences, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=GILD

On Wednesday, shares of Abbott Laboratories recorded a trading volume of 3,728,920 shares, which was below the three months average volume of 7,009,774 shares. The stock ended the day 1.11% higher at 58.28. The share price has gained 37.75% from its 52-week low with a 52-week trading range of 42.31 - 64.60. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $59.36 is greater than its 200-day moving average of $54.78. Shares of Abbott Laboratories are trading at a Price to Earnings ratio of 215.06. Shares of Abbott Laboratories have fallen roughly 0.95 percent in the past month and are up 2.12 percent year-to-date.

Access RDI's Abbott Laboratories Research Report at:
https://rdinvesting.com/news/?ticker=ABT

Our Actionable Research on Gilead Sciences, Inc. (NASDAQ:GILD) and Abbott Laboratories (NYSE:ABT) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com


Advertisement